Filter Releases
 
News Releases
Date Title and Summary View
Mar 13, 2002
TUSTIN, Calif., Mar 13, 2002 (BW HealthWire) -- Avid Bioservices, Inc. (Avid), a wholly-owned subsidiary of Peregrine Pharmaceuticals (Nasdaq: PPHM), today announced that it has signed a manufacturing supply agreement with a biotechnology company for the current Good Manufacturing Practices (cGMP) production of a monoclonal antibody anticipated...
Mar 6, 2002
TUSTIN, Calif., Mar 6, 2002 (BW HealthWire) -- Avid Bioservices Inc. (Avid), a wholly owned subsidiary of Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM), and Seradyn Inc., a subsidiary of Apogent Technologies Inc., entered into a long-term supply agreement in which Avid will manufacture a key raw material for a therapeutic drug monitoring kit tha...
Mar 4, 2002
TUSTIN, Calif., Mar 4, 2002 (BW HealthWire) -- Peregrine Pharmaceuticals (Nasdaq:PPHM) today announced the issuance of U.S. Patent No. 6,342,221 covering the use of a new category of therapeutic agents within its Vascular Targeting Agent (VTA) technology. The new patent covers VTAs that deliver therapeutic agents such as toxins, chemotherapeuti...
Feb 28, 2002
TUSTIN, Calif., Feb 28, 2002 (BW HealthWire) -- OXiGENE Inc. (Nasdaq:OXGN)(SSE:OXGN) and Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM) today announced an agreement to conclude their Arcus Therapeutics, LLC joint venture (Arcus). Under the terms of the agreement, Peregrine will pay OXiGENE $2,000,000 and will reacquire full rights and inter...
Feb 4, 2002
TUSTIN, Calif., Feb 4, 2002 (BW HealthWire) -- Peregrine Pharmaceuticals (Nasdaq:PPHM) today announced that it has closed an offering for $2.2 million off of the shelf Registration Statement on Form S-3 it filed with the Securities and Exchange Commission. The shares of common stock were sold to two institutional investors. The company no...
Jan 29, 2002
TUSTIN, Calif., Jan 29, 2002 (BW HealthWire) -- Peregrine Pharmaceuticals (Nasdaq:PPHM) today announced the issuance of U.S. Patent No. 6,342,219 covering the use of new antibodies for cancer treatment. The patent, titled "Antibody Compositions for Selectively Inhibiting VEGF," specifically covers antibodies that bind to and selectively ne...
Jan 8, 2002
TUSTIN, Calif., Jan 8, 2002 (BW HealthWire) -- Wholly Owned Subsidiary to Provide Biologics Manufacturing and Product Development Services to Biotechnology Industry Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM) today announced that it has formed Avid Bioservices Inc. as a wholly owned subsidiary. Avid will pro
Dec 20, 2001
TUSTIN, Calif., Dec 20, 2001 (BW HealthWire) -- Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM) today announced that it has initiated human antibody generation against two additional targets with Xenerex Biosciences, a wholly owned subsidiary of Avanir Pharmaceuticals (AMEX:AVN). Both of these antibodies are being developed to potentially be ...
Dec 17, 2001
TUSTIN, Calif., Dec 17, 2001 (BW HealthWire) -- Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM) announced today that it will conduct its quarterly conference call on Thursday, Dec. 20 at 11 a.m. (ET). In order to participate in this call, phone 888/857-6929 at least five minutes before the call is scheduled to begin. An audio replay will be a...
Dec 17, 2001
TUSTIN, Calif, Dec 17, 2001 (BW HealthWire) --Study Concludes That Human TNT Antibody Shows Promise for Human Use Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM) today announced that an article published in the journal Hybridoma and Hybridomics has verified the similarity of chimeric and human Tumor Necrosis Therapy (TNT) monoc...
Dec 13, 2001
TUSTIN, Calif., Dec 13, 2001 (BW HealthWire) -- Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM) today announced that it has concluded a successful meeting with the U.S. Food and Drug Administration (FDA). Peregrine and representatives from the FDA agreed upon the design of a pivotal Phase III study for the treatment of recurrent glioblastoma ...
Nov 19, 2001
TUSTIN, Calif.--(BW HealthWire)--Nov. 19, 2001-- Proceeds Will Allow Company to Advance Phase III Clinical Trials and Contract Manufacturing Operations Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM), today announced that it has closed an offering for $5.75 million off of the Shelf ...
Nov 16, 2001
TUSTIN, Calif.--(BW HealthWire)--Nov. 16, 2001--Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM) today announced that image fusion data from its Phase II Cotaraâ„¢ trial for malignant glioma will be presented in a poster presentation at the First Quadrennial Meeting of the World Federation of Neuro-Oncology being held in Washington, DC from...
= add release to Briefcase

Search Investor Relations